278 related articles for article (PubMed ID: 34158318)
1. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
[TBL] [Abstract][Full Text] [Related]
2. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
[TBL] [Abstract][Full Text] [Related]
3. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
Abu-Sbeih H; Ali FS; Naqash AR; Owen DH; Patel S; Otterson GA; Kendra K; Ricciuti B; Chiari R; De Giglio A; Sleiman J; Funchain P; Wills B; Zhang J; Naidoo J; Philpott J; Gao J; Subudhi SK; Wang Y
J Clin Oncol; 2019 Oct; 37(30):2738-2745. PubMed ID: 31163011
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
Gong Z; Wang Y
JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H; Faleck DM; Ricciuti B; Mendelsohn RB; Naqash AR; Cohen JV; Sellers MC; Balaji A; Ben-Betzalel G; Hajir I; Zhang J; Awad MM; Leonardi GC; Johnson DB; Pinato DJ; Owen DH; Weiss SA; Lamberti G; Lythgoe MP; Manuzzi L; Arnold C; Qiao W; Naidoo J; Markel G; Powell N; Yeung SJ; Sharon E; Dougan M; Wang Y
J Clin Oncol; 2020 Feb; 38(6):576-583. PubMed ID: 31800340
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
[TBL] [Abstract][Full Text] [Related]
8. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
Grover S; Ruan AB; Srivoleti P; Giobbie-Hurder A; Braschi-Amirfarzan M; Srivastava A; Buchbinder EI; Ott PA; Kehl KL; Awad MM; Hodi FS; Rahma OE
JCO Oncol Pract; 2020 Sep; 16(9):e933-e942. PubMed ID: 32401685
[TBL] [Abstract][Full Text] [Related]
9. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
[TBL] [Abstract][Full Text] [Related]
14. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
[TBL] [Abstract][Full Text] [Related]
15. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.
Lo YC; Price C; Blenman K; Patil P; Zhang X; Robert ME
Am J Clin Pathol; 2021 Jul; 156(2):214-228. PubMed ID: 33555016
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551
[TBL] [Abstract][Full Text] [Related]
18. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
[TBL] [Abstract][Full Text] [Related]
19. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
20. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
